A center of excellence for commercialization driven R&D in healthcare biotechnology
To implement R&D, develop human capital & expertise, strengthen strategic collaboration in global healthcare biotechnology leading to commercialization
Healthcare biotechnology serves a pivotal role in the realization of the National Biotechnology Policy (NBP) devised in 2005. The abundance of natural resources found within our borders will serve to drive biotechnology as a new economic engine in the near future. Following a decision by the Cabinet on the implementation of the NBP (Memorandum MOSTI No. 882/2534/2006), the Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm) was established on 29th November 2006 under the Ministry of Science, Technology and Innovation in order to spearhead this initiative by delivering world-class R&D to accelerate the discovery, development and commercialization of pharmaceutical and nutraceutical products.
In setting up the institute, the national Economic Planning Unit (EPU) has outlined and approved five major R&D thrust areas to be implemented by IPHARM under the Ninth Malaysia Plan (RMK 9). This will encompass critical development aspects which will enable locally developed biotechnology goods to meet rigorous international quality standards in order to penetrate the global market.
Blok 5-A, Halaman Bukit Gambir, Penang, 11700, Malaysia